Brain Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Brain Cancer Market Outlook

Thelansis’s “Brain Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Brain Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Brain Cancer Overview

Brain cancer refer to abnormal growth of brain or central nervous system (CNS) cells. These abnormal cells form a mass called a tumor, which can interfere with normal brain functions. It can be primary or secondary. Primary brain tumors originate in the brain and can be benign or malignant. Benign tumors are noncancerous and grow slowly. They do not invade nearby tissues and are less likely to recur after treatment. Malignant tumors, on the other hand, are cancerous and grow rapidly. They invade surrounding tissues and may recur even after treatment. Secondary brain tumors originate in different body parts and spread to the brain. Cancer cells from primary tumors in organs such as the lung, breast, kidney, colon, or stomach can travel through the bloodstream or lymphatic system and form secondary tumors in the brain. Approximately 20% of brain cancer cases are due to brain metastasis. Brain cancer symptoms can vary depending on the location and size of the tumor. Common symptoms include frequent headaches, seizures, changes in vision (such as double vision or blurred vision), hearing and speech problems, difficulty with balance and coordination, cognitive changes, and personality changes. However, these symptoms can also be caused by other conditions, so it's important to consult a healthcare professional for an accurate diagnosis. Brain tumors are classified into grades based on their growth rate and aggressiveness. The grading system helps determine the treatment approach and prognosis. High-grade tumors, also known as malignant or aggressive tumors, grow rapidly and are more likely to spread to other brain or spinal cord parts. Low-grade tumors, also called benign or slow-growing tumors, tend to grow more slowly and are less likely to invade surrounding tissues. Diagnosis of brain cancer typically involves a combination of imaging tests, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, and a biopsy, which involves the removal of a small sample of the tumor for examination under a microscope. Brain cancer treatment options include surgery, radiation therapy, and chemotherapy. The choice of treatment depends on various factors, including the type and grade of the tumor, its size and location, the patient's age and overall health, and the presence of any genetic mutations or biomarkers. In 2023, an estimated 24,810 adults will be diagnosed with primary cancerous brain and spinal cord tumors in the United States. Of these, 14,280 will be men and 10,530 will be women. Brain tumors account for 85% to 90% of all primary central nervous system (CNS) tumors.

• It is estimated that 5,230 children under 20 will also be diagnosed with a CNS tumor in the US in 2023.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: